RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2-positive locally advanced muscle-invasive urothelial bladder cancer: a multi-center phase Ib/II study (HOPE-03)
机构:[1]Abdominal Oncology Ward, Division of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.四川大学华西医院[2]Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.四川大学华西医院
National Natural Science Foundation of China, Grant/Award
Number: 81802445; Science & Technology Department of Sichuan
Province, Grant/Award Number: 2022NSFSC1564.
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2023]版:
大类|3 区医学
小类|3 区肿瘤学
最新[2023]版:
大类|3 区医学
小类|3 区肿瘤学
第一作者:
第一作者机构:[1]Abdominal Oncology Ward, Division of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
通讯作者:
推荐引用方式(GB/T 7714):
Wen Feng,Lin Tianhai,Zhang Peng,et al.RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2-positive locally advanced muscle-invasive urothelial bladder cancer: a multi-center phase Ib/II study (HOPE-03)[J].Frontiers In Oncology.2023,13:1233196.doi:10.3389/fonc.2023.1233196.
APA:
Wen Feng,Lin Tianhai,Zhang Peng&Shen Yali.(2023).RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2-positive locally advanced muscle-invasive urothelial bladder cancer: a multi-center phase Ib/II study (HOPE-03).Frontiers In Oncology,13,
MLA:
Wen Feng,et al."RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2-positive locally advanced muscle-invasive urothelial bladder cancer: a multi-center phase Ib/II study (HOPE-03)".Frontiers In Oncology 13.(2023):1233196